{
    "clinical_study": {
        "@rank": "82445", 
        "arm_group": [
            {
                "arm_group_label": "1% diclofenac sodium gel", 
                "arm_group_type": "Active Comparator", 
                "description": "Diclofenac sodium 1% gel  4 grams applied topically Q6 hours for 48 hours"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo gel 4gm applied topically Q6H for 48 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate analgesic efficacy of Topical Voltaren Gel\n      (diclofenac sodium gel) 1% applied QID compared to Placebo in Subjects Experiencing Delayed\n      Onset Muscle Soreness."
        }, 
        "brief_title": "An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Delayed Onset Muscle Soreness", 
        "condition_browse": {
            "mesh_term": [
                "Pain", 
                "Muscular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who provide written informed consent prior to enrollment\n\n          -  Male or female and 18 to 35 years of age.\n\n          -  Patients who not engaged in regular lower extremity fitness activities for more than\n             2   times per week for \u22652 consecutive weeks in the past 6 months prior to screening.\n\n          -  Female patients are eligible only if all of the following apply:\n\n               -  Not pregnant (subjects of child bearing potential must have a negative beta\n                  human chorionic gonadotropin (\u03b2-hCG) pregnancy test at screening);\n\n               -  Not lactating;\n\n               -  Not planning to become pregnant within the duration of the study;\n\n          -  Patients who are willing and capable of understanding and cooperating with the\n             requirements of the study.\n\n          -  Patients able to understand and communicate in English.\n\n        Randomization Inclusion Criteria:\n\n          -  Patients who report a DOMS score \u22654 at rest (numerical rating scale of 0 to 10, where\n             0 is no pain and 10 is worst pain imaginable) secondary to delayed muscle soreness on\n             both right and left legs.  The DOMS scores at rest reported for each leg must be\n             within 3 points of each other.\n\n          -  Patients must report a categorical pain rating of moderate to severe for each leg on\n             a scale of none, mild, moderate, or severe prior to randomization.\n\n        Exclusion Criteria:\n\n        Patients who report a DOMS score \u22654 at rest (numerical rating scale of 0 to 10, where 0 is\n        no pain and 10 is worst pain imaginable) secondary to delayed muscle soreness on both\n        right and left legs.  The DOMS scores at rest reported for each leg must be within 3\n        points of each other.\n\n          -  Patients must report a categorical pain rating of moderate to severe for each leg on\n             a scale of none, mild, moderate, or severe prior to randomization.\n\n          -  Have a body mass index of >32 kg/m2\n\n          -  History of active or suspected esophageal, gastric, pyloric channel, or duodenal\n             ulceration or bleeding within 30 days preceding screening.\n\n          -  Psychiatric disease including major depression, bipolar disorder, or anxiety, or\n             other medical condition that, in the opinion of the Investigator, would interfere\n             with the evaluation of study drug efficacy or safety\n\n          -  History of clinically significant cardiovascular, cerebrovascular, metabolic,\n             pulmonary, neurological, hematological, autoimmune, psychiatric or endocrine\n             disorders, including individuals with Type I or Type II diabetes, or other clinically\n             significant medical condition that, in the opinion of the Investigator, may preclude\n             safe study participation.\n\n          -  Have had surgery or scheduled to undergo surgery of the hips or knees within 6 months\n             prior to screening and/or during the study participation.\n\n          -  Have significant biomechanical abnormality in the lower extremity that would preclude\n             study evaluations, such as: peripheral or central neurological disease, significant\n             back pain; symptomatic osteoarthritis of the hips, knew, or feet, or other painful\n             conditions of the lower extremities.\n\n          -  Have any type of orthopedic and/or prosthetic device or any skin abnormalities on the\n             legs that may interfere with local tolerability.\n\n          -  Currently taking corticosteroids or topical analgesic or anti inflammatory treatment\n             whose the duration of action may affect study evaluations.\n\n          -  Malignancy in the last 5 years, with the exception of nonmetastatic basal cell or\n             squamous cell carcinoma of the skin that has been surgically cured, or any Stage 1\n             cancer or carcinoma in situ cured by resection or localized radiation at least 5\n             years prior to screening with no evidence of recurrence.\n\n          -  History of allergy (cutaneous or systemic), hypersensitivity, or asthma to any of the\n             following: diclofenac, paracetamol, acetylsalicylic acid, salicylic acid, other NSAID\n             or cyclooxygenase 2-specific inhibitor (COXIB) or known intolerance (cutaneous or\n             systemic) to any of the ingredients in the gel, such as isopropyl alcohol or\n             propylene glycol.\n\n          -  History of known narcotic, analgesic, or alcohol abuse.\n\n          -  Any cognitive impairment that would, in the opinion of the Investigator, preclude\n             study participation or compliance with study procedures (e.g., Alzheimer's dementia).\n\n          -  Previously received an investigational product within 30 days before the scheduled\n             dose of study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087748", 
            "org_study_id": "LCR-VOL-01C"
        }, 
        "intervention": [
            {
                "arm_group_label": "1% diclofenac sodium gel", 
                "intervention_name": "1% diclofenac sodium gel", 
                "intervention_type": "Drug", 
                "other_name": "Voltaren gel"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "gel manufactured to mimic Diclofenac sodium1% gel", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Analgesics", 
                "Diclofenac"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "DOMS", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "anne@lotuscr.com", 
                "last_name": "Anne Arriaga"
            }, 
            "contact_backup": {
                "email": "neil@lotuscr.com", 
                "last_name": "Neil Singla, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Lotus ClinicalResearch,LLC"
            }, 
            "investigator": {
                "last_name": "Neil Singla, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness", 
        "overall_contact": {
            "email": "anne@lotuscr.com", 
            "last_name": "Anne Arriaga"
        }, 
        "overall_official": {
            "affiliation": "Lotus Clinical Research, LLC", 
            "last_name": "Neil Singla, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess analgesic efficacy of Topical Voltaren\u00ae gel compared to placebo in the reduction of the pain associated with delayed onset muscle soreness.  The statistical comparison of interest will be the mean reduction in DOMS scores on movement in the leg receiving Topical Voltaren\u00ae gel versus the leg receiving placebo over the first 24H post treatment initiation.", 
            "measure": "To assess analgesic efficacy of Topical Voltaren\u00ae gel compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087748"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lotus Clinical Research, LLC", 
            "investigator_full_name": "Neil Singla", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Lotus Clinical Research, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Lotus Clinical Research, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}